16th CEO Survey: Pharmaceuticals and Life Sciences findings
The 16th Annual Global CEO Survey was launched January 22, 2013 in Davos, Switzerland. This year we interviewed over 1,300 of the world’s chief executives in over 60 countries, including 120 Canadian CEOs. In this year’s survey Dealing with disruption: adapting to survive,for business leaders across the world, ‘expect the unexpected’ has become the mantra. Organizations need to develop a new characteristic: resilience. They need the ability to ride out the immediate impact of shocks, with a long-term capacity to adapt to constantly-changing conditions.
This year we interviewed 90 Pharmaceuticals and Life Sciences CEOs in 37 countries. We also spoke in-depth with Yasuchika Hasegawa of Takeda. Pharmaceuticals and life sciences execs say they’re balancing the needs of patients and society while walking the regulatory high-wire in this year’s 16th Annual Global CEO Survey.
MoneyTreeTM venture capital funding: Double digit dip
Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries dropped 14% during 2012 but improved at year-end.
According to the MoneyTree Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA) based on data provided by Thomson Reuters, during the fourth quarter of 2012, investment in the sector rose 11% to $1.9 billion from $1.7 billion during the third quarter. The number of life science deals rose 12%, from 187 during the third quarter to 209 during the final quarter of 2012. Read the full report.
CMS shines light on Transparency Final Rule: Insights and impact
Designed to create and promote greater transparency across health care markets, the Transparency Program requires applicable manufacturers to collect, aggregate, and report payments or transfers of value to physicians and teaching hospitals was well as for physician ownership or investment interests in manufacturers and group purchasing organizations. To gauge the significance of the impact of the Final Rule, one only need to consider the position of the Center for Medicare and Medicaid Services (CMS) that it has the right to audit the reportable data and documentation. Click here to read the full report.